Sign In
NewsRadar

Vivet Therapeutics

Vivet Therapeutics is developing gene therapy treatments for rare, inherited metabolic diseases. It is building a pipeline based on Adeno Associated Virus (AAV) technologies. Vivet's lead program, VTX801, is an investigational gene therapy for Wilson disease. This rare genetic disorder is caused by a defective gene in liver cells encoding the ATP7B protein, which reduces the liver's ability to regulate copper levels in the liver and other tissues.

• Show past press releases
• Edit this company

Contact Information
Address:
 
 
Phone:
Web:
Contact:
 
 
29 rue Tronchet
Paris 75008
France
+33-684-755-087
http://www.vivet-therapeutics.com
Jean-Philippe Combal
+33-684-755-087

Company Facts
Founded:
Founders:
CEO:Jean-Philippe Combal
CTO or technical lead:
CFO or finance director:
Head of Sales:
Head of Marketing:

Stage:Early Stage
Category:Biotechnology & Healthcare
Sector:Biopharmaceuticals
Employees:
Profitability:
Funding raised:Yes
Funding sought:
Seeking Partnerships:

Non-executive Board Members

Key Customers

Key Business Partners

Key Competitors

Capital Raised
DateSizeInvestors
To view this information you must be signed in and subscribed to the online dataservice, sign in here.

To read more about the Online data service click here

Public Offerings
DateTypeExchange
No public offerings


Data


26,231
Tech investments
From our Online Data Service
16,945
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises 1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.